Wiwanitkit, Viroj2009-05-282009-05-282008-01-12Wiwanitkit V. Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy. Indian Journal of Dermatology, Venereology and Leprology. 2008 Jan-Feb; 74(1): 32-4http://imsear.searo.who.int/handle/123456789/52980BACKGROUND AND AIMS: Mycobacterium leprae is an obligate intracellular pathogen. Ligand-binding is an important factor in the success of chemoprevention and chemotherapy. A new drug that can inhibit M. leprae binding to and activation of, ErbB2 and Erk1/2 in primary Schwann cells is the new therapeutic option. However, the ligand-binding pattern of ErbB2 has never been clarified. METHODS: In this work, the author performed a ligand-binding prediction for ErbB2 using a new bioinformatics tool. RESULTS: According to this study, nine strong possible ligands can be identified. CONCLUSION: These sites can be useful for further drug-development studies.engBinding SitesComputational BiologyDrug DesignHumansLeprosy --metabolismLigandsMycobacterium leprae --metabolismPredictive Value of TestsProtein BindingReceptor, erbB-2 --chemistryVirulenceJournal Article